Reported 3 days ago
AstraZeneca has signed a $555 million deal with Algen Biotechnologies to develop therapies using Algen's AI-driven gene-editing platform, focusing on immune system disorders. The agreement grants AstraZeneca exclusive rights to develop and market any resulting approved therapies, in exchange for payments to Algen. This partnership aligns with AstraZeneca's strategy to enhance its cell and gene therapy initiatives, as the pharmaceutical industry increasingly embraces AI for drug development.
Source: YAHOO